Becton, Dickinson, and Company (BDX), or BD, is a leading player in laboratory diagnostic solutions for hospitals and laboratories around the world. BD’s Max and Kiestra platforms are some of BD’s key products in the diagnostics space.
BD has a strong product pipeline of innovative products under development in its LifeSciences segment, which includes the company’s diagnostic offerings.
New diagnostic test in Europe
On September 26, 2017, BD announced the launch of its Phoenix CPO (carbapenemase-producing organisms) detection test. The test is the first phenotypic test for the detection and classification of CPO.
This new test is available in Europe as part of the BD Phoenix automated microbiology system. The test is also expected to potentially combat an increase in AMR (antimicrobial resistance). The test is fully integrated within BD’s Phoenix panels.
Emerging sexually-transmitted pathogens
On September 20, 2017, BD announced an agreement with Euroclone, an Italy-based diagnostic firm, for the development and distribution of molecular tests for the detection of emerging sexually-transmitted pathogens.
These assays will expand the BD Max portfolio offerings. For mitigating the threat of AMR, other tests offered by BD include BD SurPath, a liquid-based Pap test, and the BD Onclarity HPV assay, a molecular test for detecting 14 high-risk HPV genotypes.
Thermo Fisher Scientific (TMO), Abbott Laboratories (ABT), and Illumina (ILMN) are some of the major competitors of BD in the diagnostics space. Investors eager to invest in BD can consider the iShares Core S&P 500 ETF (IVV) to diversify company-specific risks. IVV has ~0.20% of its total holdings in BD.